Exenatide Plus Dapagliflozin Significantly Reduces A1C Compared to Either Drug Alone: DURATION-8 Results

Date: 
December, 2016

December 2016. This randomized controlled trial examined the effect on A1C of exenatide plus dapagliflozin compared with either drug alone. Over 28 weeks, among patients with type 2 diabetes, exenatide plus dapagliflozin reduced A1C by 2.0%. This was significant versus a reduction of 1.6% in the exenatide group (95% confidence interval [CI], −0.6 to −0.1; P=0.004), and compared to a reduction of 1.4% in the dapagliflozin group (95% CI, –0.8 to −0.3; P<0.001). Additionally, exenatide plus dapagliflozin was superior to either drug alone for all secondary efficacy endpoints, including greater reductions in fasting plasma and postprandial glucose, more patients with A1C levels &lt7.0%, greater weight loss, a greater proportion of patients with weight loss ≥5%, and greater reductions in systolic blood pressure (all P≤0.025). Among patients in the exenatide plus dapagliflozin group, 57% experienced adverse events, compared with 54% and 52% in the exenatide and dapagliflozin groups, respectively. There were no episodes of major or minor hypoglycemia.Click here to read full article